---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-036285"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:17:39.089071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026

## Summary
- Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.
- CLN-418/HBM7008 is a clinical-stage (Phase 1) B7H4 x 4-1BB bispecific immune activator for solid tumors.
- Cash and investments $550M at end 2022; after $25M upfront would be $525M; expects cash to last into 2026.
- Company expects to have six clinical-stage assets in pipeline by end 2023.

## SEC filing metadata
- accession: 0001193125-23-036285
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/0001193125-23-036285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/d436936d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-036285
- JSON: https://secwatch.observer/filing/0001193125-23-036285.json
- Plain text: https://secwatch.observer/filing/0001193125-23-036285.txt

## Key facts
- Material Agreements
  Cullinan Therapeutics, Inc. entered into License Agreement with Harbour BioMed US Inc. valued at $25 million upfront license fee (effective 2023-02-13).
  - Action: entry
  - Agreement: license
  - Counterparty: Harbour BioMed US Inc.
  - Value: $25 million upfront license fee
  - Effective: 2023-02-13
  source text: On February 13, 2023, Cullinan Oncology, Inc. (the "Company") and Harbour BioMed US Inc. ("Harbour") entered into a License and Collaboration Agreement (the "License Agreement"), pursuant to which Harbour granted to the Company an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/0001193125-23-036285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.